List of Excipients in Branded Drug CRIXIVAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme Corp	CRIXIVAN	indinavir sulfate	0006-0570	ANHYDROUS LACTOSE	1969-12-31
Merck Sharp & Dohme Corp	CRIXIVAN	indinavir sulfate	0006-0570	GELATIN	1969-12-31
Merck Sharp & Dohme Corp	CRIXIVAN	indinavir sulfate	0006-0570	MAGNESIUM STEARATE	1969-12-31
Merck Sharp & Dohme Corp	CRIXIVAN	indinavir sulfate	0006-0570	TITANIUM DIOXIDE	1969-12-31
STAT Rx USA LLC	CRIXIVAN	indinavir sulfate	16590-064	ANHYDROUS LACTOSE	1969-12-31
STAT Rx USA LLC	CRIXIVAN	indinavir sulfate	16590-064	GELATIN	1969-12-31
STAT Rx USA LLC	CRIXIVAN	indinavir sulfate	16590-064	MAGNESIUM STEARATE	1969-12-31

Crixivan Excipient Strategy and Commercial Opportunities for Indinavir

Last updated: September 9, 2026

Crixivan, Merck’s indinavir sulfate product, is an off-patent HIV protease inhibitor with limited branded commercial value and weak prospects for a new standalone launch. The viable opportunity is a low-cost generic or specialty-market product supported by a simple, robust capsule formulation. Excipient innovation can improve manufacturability, moisture control, dissolution consistency and supply economics, but it is unlikely to overcome indinavir’s clinical disadvantages, including high dosing frequency, food restrictions, nephrolithiasis risk and obsolescence relative to boosted protease inhibitors and integrase inhibitors.

What is Crixivan and how is it formulated?

Crixivan is an oral capsule containing indinavir sulfate, equivalent to indinavir. The U.S. product was approved by the FDA in 1996 for HIV-1 infection and was marketed in 200 mg and 400 mg capsule strengths.[1]

The product uses a conventional immediate-release hard-capsule platform. The U.S. prescribing information identifies the principal inactive ingredients as:

Formulation component	Role
Lactose anhydrous	Diluent and capsule-fill bulking agent
Microcrystalline cellulose	Filler, dry binder and flow aid
Crospovidone	Superdisintegrant
Magnesium stearate	Lubricant
Gelatin	Hard-capsule shell
Titanium dioxide and colorants	Capsule identification and appearance
Printing ink	Product identification

The formulation is not technically complex. Its commercial performance depends more on API handling, dissolution control, moisture management and capsule-fill consistency than on sophisticated excipient technology.

What technical constraints affect indinavir capsule development?

Indinavir sulfate presents several development considerations:

1. The dose is relatively high. Standard dosing historically required 800 mg every eight hours, which creates a substantial capsule-fill burden and weakens the commercial case for low-dose or highly specialized dosage forms.[1]

2. Crixivan is administered on an empty stomach, generally one hour before or two hours after meals. The product label also instructs patients to maintain substantial fluid intake to reduce the risk of kidney stones.[1]

3. Indinavir has a narrow practical formulation window. Excessive hydrophobic lubrication, poor powder flow or inadequate disintegration can reduce dissolution performance.

4. The product requires strong batch-to-batch control for assay, content uniformity, dissolution, water content and degradation products.

5. The capsule shell and packaging must protect the formulation from moisture without creating excessive packaging cost.

The core excipient strategy should therefore favor established, globally available materials rather than novel excipients requiring additional regulatory justification.

What excipient strategy is most suitable for generic Crixivan?

A generic indinavir capsule should generally retain a conventional immediate-release formulation unless a specific product-development objective justifies reformulation.

Recommended baseline formulation strategy

The most commercially defensible platform would use:

• Anhydrous lactose or another established diluent
• Microcrystalline cellulose for compactability and flow
• Crospovidone for rapid disintegration
• Low-level magnesium stearate for lubrication
• A hard-gelatin or hypromellose capsule shell
• High-barrier blister or bottle packaging with a desiccant where required

The objective should be pharmaceutical equivalence and manufacturing reliability, not a differentiated excipient story. A generic applicant would benefit from minimizing formulation changes from the reference product because a conventional formulation can reduce development complexity and support an efficient ANDA pathway.

Should lactose be replaced?

Lactose replacement could be commercially relevant if the manufacturer wants a lactose-free product, reduces Maillard-reaction concerns or improves global market positioning. Suitable alternatives could include:

• Mannitol
• Dibasic calcium phosphate
• Pregelatinized starch
• Additional microcrystalline cellulose
• Coprocessed filler systems

The choice must be driven by powder flow, capsule density, dissolution and stability. A lactose-free claim would have limited demand in HIV markets unless supported by a clear patient or procurement requirement. Replacing lactose can also increase cost and complicate bioequivalence development without creating material clinical value.

Should gelatin be replaced with hypromellose?

A hypromellose capsule could support vegetarian, religious or supply-chain positioning. It may also offer a differentiated global-market profile. The commercial benefit is uncertain because Crixivan is an established capsule product with low patient demand.

Hypromellose capsules can differ from gelatin capsules in moisture behavior, mechanical properties, fill weight and dissolution under certain conditions. A switch would require comparative dissolution testing and potentially more extensive formulation work. It is most defensible when targeting markets where non-animal capsules materially improve procurement access.

What formulation patents protect Crixivan?

Crixivan’s original protection was based primarily on historical compound, pharmaceutical composition and antiviral-use patents associated with indinavir and Merck’s HIV protease inhibitor program. Those rights were filed during the 1980s and 1990s and are no longer expected to provide a meaningful barrier to a new U.S. generic launch.

The key commercial points are:

Issue	Commercial assessment
New chemical entity exclusivity	Expired
Original compound and composition patents	Expired or commercially exhausted
U.S. pediatric exclusivity	Historical, expired
Current branded exclusivity	None expected
Biosimilar exclusivity	Not applicable
Generic pathway	ANDA, subject to current FDA reference-product status
Reformulation patent risk	Possible only if a new formulation is independently patented and commercially relevant

Because Crixivan is a small-molecule product, it does not face biosimilar competition. Any competing product would be a generic or a separately developed reformulation.

A manufacturer should not assume that all relevant rights are absent solely because the original product is old. The Orange Book, patent assignment records and applicable national registers should be reviewed before filing. The principal risk is unlikely to be a basic excipient combination. It is more likely to involve a surviving method-of-use claim, a manufacturing process claim or a later formulation patent in a specific jurisdiction.[2]

When did Crixivan lose exclusivity and what is the Orange Book status?

Crixivan received FDA approval in March 1996.[1] Its original regulatory and patent exclusivity periods have expired. The reference product is therefore an established generic candidate rather than a protected innovative product.

The FDA Orange Book remains the controlling source for current U.S. reference-product identification, listed patents and exclusivity information.[2] Historical Crixivan listings may remain relevant for ANDA litigation analysis even if the branded product is no longer actively promoted or widely supplied.

A new applicant should assess:

• Whether Crixivan remains the designated reference listed drug
• Whether the relevant strength and dosage form are still active in the FDA database
• Whether any patents remain listed
• Whether a 30-month stay could arise from a Paragraph IV notice
• Whether the proposed label can omit obsolete or protected indications under a section viii strategy

Are Paragraph IV challenges and patent litigation relevant to Crixivan?

Paragraph IV risk is likely low for the original Crixivan product because the relevant protection is historic. A generic applicant would still need to certify against any listed patent in the Orange Book.

Potential filing positions include:

• Paragraph III certification if a listed patent remains unexpired
• Paragraph IV certification if the applicant challenges validity, enforceability or infringement
• Paragraph I or II certification if the relevant patent information is absent or not applicable
• Section viii carve-out for a protected method of use, where legally available

Crixivan is not known as a current high-value patent-litigation product. The commercial value of litigating an old indinavir patent would generally be limited unless the applicant expects meaningful sales in a protected market or the patent covers a differentiated formulation with a long remaining term.

No major current settlement-driven generic launch framework is expected to determine the U.S. market. Any historical settlements would need to be checked against the relevant jurisdiction and product strength before being used in a launch model.

What FDA regulatory pathway applies to a generic Crixivan product?

The likely U.S. pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.[3]

Core development requirements would include:

• Same active ingredient
• Same dosage form
• Same route of administration
• Equivalent strength
• Comparable labeling, subject to permitted carve-outs
• Comparative dissolution
• Stability data
• Manufacturing controls
• Impurity and degradation-product characterization
• Bioequivalence under FDA requirements

A 505(b)(2) application could be considered for a materially different dosage form, delivery system or formulation. That route would be more expensive and would need a commercial rationale. A sustained-release product, fixed-dose combination or alternative administration system could qualify for a differentiated strategy, but the clinical demand for such a product is weak.

What commercial opportunities exist for Crixivan excipients?

The most credible opportunities are in manufacturing and supply rather than premium pricing.

1. Generic supply for legacy HIV markets

A manufacturer could supply indinavir capsules to public-sector buyers, country programs or markets where older antiretroviral regimens remain in use. The addressable market is constrained by the global shift toward integrase inhibitor-based treatment. WHO guidelines favor dolutegravir-based regimens because of efficacy, tolerability, resistance profile and simplified dosing.[4]

A low-cost formulation may still be commercially viable where:

• Procurement budgets are limited
• Existing treatment protocols use older protease inhibitors
• Local registration requirements are manageable
• Supply continuity is more important than therapeutic modernization
• Competitor supply is unreliable

2. Excipient and capsule supply agreements

Excipient companies could target manufacturers with:

• Direct-compression lactose or lactose-free filler systems
• Low-moisture microcrystalline cellulose
• Crospovidone grades optimized for rapid capsule disintegration
• Hypromellose capsule shells
• Moisture-barrier blister films
• Integrated excipient premixes

The value proposition is lower batch failure risk, improved flow and reduced process development time. It is unlikely to support a high-margin, drug-specific licensing model.

3. Reformulation and fixed-dose combinations

A fixed-dose indinavir combination with a pharmacokinetic booster could reduce dosing frequency, but the opportunity is weak. Ritonavir and cobicistat-based treatment has moved toward more effective and better-supported regimens. Any new combination would face clinical, regulatory and commercial competition from established antiretroviral products.

A smaller opportunity could exist in:

• Lower-pill-burden formulations
• Pediatric or low-body-weight dosing
• Regional products for legacy treatment programs
• Hospital reserve supply
• Compounded or extemporaneous-use support where lawful

These opportunities would require a clear procurement or access rationale.

How strong is the Crixivan patent estate?

The original Crixivan estate is weak as a current commercial barrier. Its age limits the value of composition-of-matter rights, and the underlying product has lost clinical priority in HIV treatment.

Patent-estate factor	Assessment
Compound protection	Expired
Product-specific exclusivity	Expired
Excipient combination protection	Low likelihood of meaningful current scope
Manufacturing barriers	Moderate if API supply is concentrated
Regulatory barrier	Moderate, because bioequivalence and quality requirements still apply
Commercial barrier	High relative to product demand
Biosimilar barrier	Not applicable

The strongest practical barrier is not intellectual property. It is the combination of low demand, high tablet or capsule burden, legacy clinical status and limited supplier economics.

What generic launch scenarios exist?

Base case: low-volume generic capsule

A manufacturer launches 200 mg and 400 mg capsules with a conventional formulation. The product competes primarily on supply reliability and price. This is the most realistic scenario.

Upside case: regional supply contract

The manufacturer secures a tender or country-specific contract in a market where indinavir remains part of a legacy regimen. Revenue is contract-dependent and unlikely to justify extensive formulation innovation.

Downside case: no commercial launch

The applicant completes development but does not launch because demand is too low, the reference product is difficult to source for comparative testing, or procurement has shifted entirely to newer antiretrovirals.

Unattractive case: premium reformulation

A new excipient system or novel delivery platform attempts to command premium pricing. The development cost and regulatory burden would likely exceed the achievable market value unless the product addresses a defined pediatric or access need.

What is the revenue exposure and competitive landscape?

Merck has not generally reported Crixivan as a separately material revenue line in recent public financial disclosures. Standalone product revenue therefore cannot be reliably modeled from company filings.

The competitive landscape includes:

• Generic indinavir products
• Ritonavir-boosted protease inhibitors
• Darunavir-based regimens
• Atazanavir-based regimens
• Dolutegravir-based integrase inhibitor regimens
• Fixed-dose combination antiretroviral products

Crixivan is commercially disadvantaged by three-times-daily dosing, fasting requirements and renal adverse-event concerns. These factors reduce the likelihood that a new entrant can obtain meaningful share through excipient differentiation alone.

Key Takeaways

• Crixivan contains indinavir sulfate in immediate-release hard capsules.
• The principal excipients are anhydrous lactose, microcrystalline cellulose, crospovidone and magnesium stearate.
• A generic product should favor a conventional, low-cost capsule formulation.
• Lactose-free and hypromellose-capsule options are technically feasible but have limited commercial justification.
• Original Crixivan exclusivity has expired; current U.S. rights should be verified through the Orange Book.
• Crixivan is a small molecule, so biosimilar risk does not apply.
• Paragraph IV litigation risk is likely low, while regulatory and supply-chain execution remain more relevant.
• The strongest opportunities are low-cost generic supply, regional tenders and excipient supply agreements.
• The weak commercial outlook reflects clinical obsolescence and limited demand, not a difficult excipient platform.
• Premium reformulation is unlikely to produce an attractive return without a defined pediatric, access or procurement need.

FAQs

Can a generic Crixivan capsule use different excipients?

Yes. A generic may use different inactive ingredients if it meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, safety and labeling. The formulation must deliver comparable performance to the reference product.

Is Crixivan suitable for a lactose-free generic product?

Technically, yes. Lactose can be replaced with mannitol, microcrystalline cellulose, dibasic calcium phosphate or another suitable diluent. The commercial benefit is likely limited unless a target market specifically requires lactose-free or allergen-controlled products.

Does Crixivan have biosimilar competition?

No. Indinavir is a chemically synthesized small molecule. Competitors enter through the generic-drug pathway, not the biosimilar pathway.

Could a new Crixivan formulation receive new patent protection?

A new formulation could potentially receive patent protection if it is novel, nonobvious and adequately disclosed. A routine substitution of one established filler for another would generally provide a weak patent position and limited commercial exclusivity.

Is indinavir still commercially relevant in HIV treatment?

Indinavir has residual relevance in selected legacy or access-constrained markets, but it is no longer a leading treatment option. Modern guidelines favor better-tolerated, simpler and more effective regimens, especially dolutegravir-based therapy.

References

1. U.S. Food and Drug Administration. (1996). Crixivan (indinavir sulfate) prescribing information. Merck & Co.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2023). ANDA submissions: Content and format. https://www.fda.gov/drugs/guidance-compliance-regulatory-information

4. World Health Organization. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. World Health Organization.